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S U M M A R Y
The place of steroids in the management of severe forms of dengue is unclear. A retrospective
observational study showed the beneﬁts of a single dose of intravenous methyl prednisolone in a highly
selected group of patients who developed severe dengue during the febrile phase of infection. We report
the case of a 14-year-old boy with dengue who developed three episodes of severe hemodynamic
compromise while having high fever, ‘myocarditis’, third space ﬂuid accumulation, progressive
reduction in urine output, and altered mentation, who made a dramatic recovery following a single dose
of intravenous methyl prednisolone. Results justify a well powered randomized controlled trial to
evaluate the efﬁcacy of this treatment in severe dengue.
 2012 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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The place of steroids in the management of severe forms of
dengue is unclear.1,2 Studies to assess the effects of steroids have
all been done in children and with the steroids given at a late stage
of dengue shock syndrome (DSS).2While some studies have shown
no beneﬁcial effects,2 two studies have shown the beneﬁts of high-
dose methyl prednisolone.2 A retrospective observational study
has also shown the beneﬁts of a single dose of intravenous (IV)
methyl prednisolone in a highly selected group of patients who
developed severe dengue during the febrile phase of infection.3
Immune mechanisms may play an important role in the
development of severe forms of dengue. Studies have shown
participation of tumor necrosis factor alpha (TNF-a), interleukin
(IL)-2, IL-6, IL-8, IL-10, IL-12, and interferon gamma (IFN-g), Th1/
Th2 immune reactions, and vascular cell adhesion molecule 1
(sVCAM-1) in the pathophysiology of dengue fever (DF) and DSS.4
The role of steroids in the management of severe shock or severe
respiratory distress is based on its ability to inhibit TNF-a and IFN-
g production, and the inhibition of IL-1b, IL-6, and IL-8.4 Steroids
have been shown to modulate dengue infection by decreasing the
cell infection rates.
We report the case of a 14-year-old patient with DF who was
given a single dose of methyl prednisolone as rescue medication at* Corresponding author.
E-mail address: ranjanp64@gmail.com (R. Premaratna).
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http://dx.doi.org/10.1016/j.ijid.2012.02.014the time he developed the third episode of dengue shock while
having high fever, third space ﬂuid accumulation, evidence of
‘myocarditis’, hepatic involvement, and deteriorating levels of
consciousness. He made a dramatic recovery following methyl
prednisolone. We wish to highlight the possible beneﬁcial effects
of a single dose of IV methyl prednisolone used as a rescue
medication in severe dengue.
2. Case report
A 14-year-old schoolboy was admitted on day 2 of a febrile
illness with headache, body aches, and vomiting. He was admitted
mainly for IV ﬂuid therapy as he could not retain oral ﬂuids. On
admission his blood pressure was 120/80 mmHg and pulse rate
was 80/min. His liver was palpable 3 cm below the right costal
margin and was mildly tender. There was no splenomegaly or free
ﬂuid in the abdomen or in the chest. Based on the initial clinical
assessment supported by investigations (Table 1), he was
suspected of having dengue and was kept under close observation.
He continued to have an intermittent high fever (range 39–41 8C).
On day 4 of the illness his blood pressure dropped to 90/60 mmHg
with a pulse rate of 90/min. At this stage an electrocardiogram
(ECG) showed T wave inversions in the anterior leads (Figure 1)
and an echocardiogram showed mild global hypokinesia with an
ejection fraction of 50%. However, his cardiac enzymes (troponin I)
were normal. Following development of the ECG changes, he
was managed with oral solutes and IV ﬂuids (either normal
saline or Hartman solution) with extreme care, based on clinicalses. Published by Elsevier Ltd. All rights reserved.
Table 1
Clinical parameters and hematological and biochemical test results from admission to hemodynamic stability
2 4 5
Time (24 h clock) 12.00 06.00 18.00 06.00 07.00 12.00 14.00 16.00 19.00 20.00 00.00
Temperature, 8C 38.8 39.2 38.9 39.2 39.5 37.8 37 40.2 37 37
Pulse/min 80 92 110 ?? 120 140 140 140 164 118 90
BP Supine (mmHg) 120/80 110/80 96/65 70/?60 70/60 92/73 70/? 117/74 ?60 108/65 117/72
BP Standing (mmHg) 110/80 110/80 90/60 ?? 120
Capil. Filling T (S) 2 2 2 >3 >3 >3 >3 <3 >3 2 2
Resp Rate (/min) 18 18 18 28 28 40 36 30 44 24 24
UOP 1.5l/24 h 0.4l/6 h 0.1 ml/kg/h 0.6 ml/kg/h 0.6 ml/kg/h 0.8 ml/kg/h 0.2 ml/kg/h 0.8 ml/kg/h 1.4 ml/kg/h
Input iv (l) Crystalloid
1.5l + 0.25l
bolus
Crystalloid
0.5l bolus
0.5l Dextran
Crystalloid
2 ml/kg/h
Dextran 0.25 l Crystalloid
2 ml/kg/h
Dextran
0.25l + MP
Crystalloid
1 ml/kg
Crystalloid
0.5 ml/kg
Input Oral (l) 1.1 1.7 Rest
Pleural Effusion Nil Nil Mild Mild Mild Moderate Moderate Moderate Moderate Moderate
Ascites Nil Nil Nil Mild Mild Mild Moderate Moderate Moderate Moderate
Hb (g/dl) 13.9 14.3 15.1 16.0 17 15.2 13.5
PCV (Fl) 41.5 43.2 45.9 49.9 48.2 40 51 49 51 48 48
Platelet ( 109/l) 131 55 17 10 4 3 4 2 4
WBC L ( 106/l) 2.8 1.5 1.6 2.2 1.2 1.3
CRP (iu/l) 6 24 48
Serum Protein (g/dl) 4.81
Serum Albumi (g/dl) 3.1
Ca++ (ionizd) mmol/L 1.10 1.13
Serum creatinine (mg/dl) 1.06
AST (IU/l) 96 407
ALT(iu/l) 73 171
Serum cholesterol 73
ECG T inv T inv T inv T inv T inv T inv Norm Norm
Blood pH 7.4 7.3 7.3
Arterial O2% 96 on 100% 92% 94% 94% 96% 96%
BP, blood pressure; UOP, urine output; IV, intravenous; MP, methyl prednisolone; Hb, hemoglobin; PCV, packed cell volume; WBC, white blood cells; CRP, C-reactive protein; AST, aspartate aminotransferase; ALT, alanine
aminotransferase; ECG, electrocardiogram; T inv, T wave inversions.
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Figure 1. Evidence of myocarditis; ECG abnormalities.
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toring. On day 5 of illness, around 06.00 h, he suddenly collapsed
with absent peripheral pulses and an unrecordable blood pressure
(Table 1), suggesting the development of DSS. As advised in the
dengue management guidelines, he was rapidly resuscitated with
IV ﬂuid boluses and dextran calculated for a period of 48 h
according to his body weight of 52 kg.5 The resuscitation was
successful, and he was transferred to intensive care for close
monitoring as he had evidence of myocarditis.
While in intensive care he continued to have a high fever (39–
41 8C) and tachycardia >110/min, and he developed two further
episodes of severe hemodynamic compromise similar to the ﬁrst
episode, at around 14.00 h and 19.00 h on the same day. At the time
of both episodes, he was given boluses of dextran infusion.
Although he could be resuscitated with a dextran bolus at 14.00 h,
it was unsuccessful at 19.00 h. During the latter episode he had a
pulse rate of 160/min in addition to a poorly recorded mid-armsystolic blood pressure of 70 mmHg and evidence of myocarditis
on ECG. His extremes were cold and lower limb pulses were not
palpable. He was confused, restless, and was in respiratory distress.
His temperature was 40.2 8C and he had a right-sided moderate
pleural effusion and moderate ascites. The respiratory rate was 36/
min and capillary O2 saturation was 96% while on 100% O2 via a
face mask. His urine output dropped to less than 0.2 ml/kg/h.
These complications made it extremely difﬁcult to make
decisions on the amount and type of ﬂuid to be used for ﬂuid
resuscitation. As the patient’s condition was deteriorating rapidly a
single dose of methyl prednisolone 500 mg in 200 ml saline was
given IV over 20 min as a rescue medication. A single dose of
meropenem 1 g IV was also given in order to counter any possible
sepsis. He had defervescence within 30 min of being given methyl
prednisolone (Figure 2), became more alert, and started to
communicate. Within 1 h, his pulse rate had reduced to 96/min,
his blood pressure remained stable above 100/80 mmHg, and his
Figure 2. Temperature chart of the patient, demonstrating rapid defervescence
following methyl prednisolone.
Figure 3. Chest X-ray of the patient obtained on day 5 of illness.
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after 3 h and a follow-up echocardiogram done after 12 h showed
an ejection fraction of 55%. His clinical parameters and haema-
tological and biochemical parameters on day 4 and 5 of illness are
shown in Table 1.
He did not develop evidence of sepsis or an increase in blood
glucose levels and continued to improve. As a precautionary
measure, meropenem was continued for 3 days. He was positive
for dengue IgM and IgG antibodies on day 6 of illness, and a serum
sample collected on admission (which was stored as part of a
dengue surveillance study) was analyzed in December 2011, and
was positive for both dengue PCR and NS1 antigen, conﬁrming the
diagnosis.
3. Discussion
This patient with dengue developed three episodes of severe
hemodynamic compromise within 12 h on day 5 of clinical illness.
All three episodes occurred while being closely monitored. He had
a high fever throughout his illness, including during the three
episodes of DSS. The highest recorded fever and the worst
hemodynamic compromise occurred during the last episode,
which resulted in restlessness and altered mentation. He did not
have febrile ﬁts and, in retrospect, his metabolic screening showed
no abnormality to account for an altered level of consciousness.
The ﬁrst two episodes of shock were managed successfully with IV
ﬂuid boluses (both crystalloids and colloids), as recommended in
the guidelines. However, our patient had evidence of myocarditis
from the outset and we had to be cautious not to overload the
patient with ﬂuid to prevent myocardial strain and also possible
pulmonary edema during the recovery phase.6 At the time of the
third episode of DSS he had clear clinical evidence of third space
ﬂuid accumulation, later conﬁrmed by chest X-ray obtained on day
5 of illness (Figure 3) and by ultrasonography. The presence of high
fever, severe hemodynamic compromise, reduced mentation,myocardial involvement, reduced urine output, and third space
ﬂuid accumulation, all suggested a rapidly deteriorating clinical
scenario. Based on our previous experience,3 we were compelled to
administer a single dose of methyl prednisolone as a rescue
measure. This led to a dramatic recovery with rapid defervescence,
hemodynamic stability, reversal of ECG changes, and improvement
in urine output, similar to our previous experience.
The clinical predicament of this patient was most likely due to
DSS with myocarditis, hepatic involvement, and encephalitis or
encephalopathy. We excluded the possibility of septic shock based
on cold peripheries with the absence of peripheral pulses at the time
of shock. There was also no evidence of bacterial infection in the
blood picture (absence of neutrophil toxic granules) and the white
blood cell count remained low until day 6. However, his C-reactive
protein was mildly elevated on day 4 and remained elevated after
the successful resuscitation. He did not develop fever or evidence of
septicemia after being given the methyl prednisolone. The
possibility of an anaphylactoid reaction to colloid solutions that
responded to methyl prednisolone is unlikely, as he had previously
received colloid solutions on two occasions (7.00 h on day 4 and
14.00 h on day 5) without developing reactions. In fact his
hemodynamic parameters improved on both occasions. The third
bolus of dextran was given at 19.00 h only after he collapsed.
In Sri Lanka the most severe outbreaks of dengue were recorded
in 2004 with 15 457 cases and 88 deaths (case fatality rate (CFR)
0.5%), in 2009 with 33 081 cases and 334 deaths (CFR 1%), and in
2010 with 34 105 cases and 246 deaths (CFR 0.7%). From the launch
of the new management guidelines for DF in 2011 up to mid-June,
there were 9136 cases with 73 deaths (CFR 0.7%). These ﬁgures
highlight the increase in dengue cases with a static CFR despite the
institution of newer resuscitation regimes. The occurrence of
severe DSS with or without severe organ involvement (myocardi-
tis, hepatitis, and encephalitis) is the most likely reason for
mortality not decreasing, and an improving ﬂuid resuscitation
alone may not be sufﬁcient to reduce mortality.
We feel that our observation of the apparent beneﬁcial effects of
a single dose of methyl prednisolone in the present case and in the
past3 warrants a randomized controlled trial to address this issue.
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